Elektrofi is a precommercial-stage biopharma formulation technology company that aims to improve the delivery of biologic therapies by enabling convenient, at-home subcutaneous self-administration.

Elektrofi was founded by aerospace engineer Chase Coffman, PhD, leveraging his academic background in fluid mechanics. The company is developing an ultra-high concentration microparticle technology called Hypercon, which converts biologics into spherical particles. This reformulation enables convenient at-home subcutaneous injections while maintaining the pharmacodynamic profile and safety of the biologics, providing value both to patients seeking improved convenience and to biopharma companies aiming to extend patent life. Elektrofi has formed partnerships with leading companies including argenx (ARGX), Johnson & Johnson (JNJ), and Eli Lilly (LLY) to reformulate both existing IV therapies, including efgartigimod (Vyvgart) and daratumumab (Darzalex), and novel therapies.